Celgene Corporation (NASDAQ:CELG)‘s stock had its “buy” rating reissued by equities research analysts at Mizuho in a report released on Friday, November 3rd.
A number of other brokerages also recently issued reports on CELG. Leerink Swann reiterated an “outperform” rating and issued a $160.00 price target (up previously from $150.00) on shares of Celgene Corporation in a report on Friday, July 28th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $170.00 price target on shares of Celgene Corporation in a report on Friday, October 20th. Vetr upgraded shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $144.39 price target for the company in a report on Monday, October 23rd. Cann reiterated a “buy” rating on shares of Celgene Corporation in a report on Thursday, October 26th. Finally, Morgan Stanley upgraded shares of Celgene Corporation from an “underweight” rating to an “equal weight” rating in a report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Celgene Corporation has an average rating of “Buy” and an average price target of $139.64.
Celgene Corporation (NASDAQ CELG) opened at $100.34 on Friday. The company has a market cap of $77,834.16, a price-to-earnings ratio of 15.45, a price-to-earnings-growth ratio of 0.76 and a beta of 1.79. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. Celgene Corporation has a 12-month low of $94.55 and a 12-month high of $147.17.
Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. Celgene Corporation’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.58 EPS. sell-side analysts expect that Celgene Corporation will post 6.67 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Celgene Corporation (CELG) Earns Buy Rating from Mizuho” was first reported by BBNS and is the property of of BBNS. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://baseballnewssource.com/markets/celgene-corporation-celg-earns-buy-rating-from-mizuho/1755056.html.
In related news, Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the sale, the director now directly owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The disclosure for this sale can be found here. Insiders have sold a total of 20,227 shares of company stock worth $2,843,956 over the last ninety days. 0.95% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its position in shares of Celgene Corporation by 5.7% in the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after acquiring an additional 3,084,227 shares during the last quarter. Vanguard Group Inc. raised its holdings in Celgene Corporation by 3.1% in the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after buying an additional 1,610,056 shares during the period. State Street Corp raised its holdings in Celgene Corporation by 2.3% in the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after buying an additional 723,844 shares during the period. Jennison Associates LLC raised its holdings in Celgene Corporation by 11.5% in the third quarter. Jennison Associates LLC now owns 14,962,407 shares of the biopharmaceutical company’s stock valued at $2,181,818,000 after buying an additional 1,546,673 shares during the period. Finally, FMR LLC raised its holdings in Celgene Corporation by 5.9% in the second quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock valued at $1,635,643,000 after buying an additional 697,250 shares during the period. 79.16% of the stock is currently owned by institutional investors and hedge funds.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with our FREE daily email newsletter.